Welcome to our dedicated page for Veraxa Biotech - Post de-SPAC SEC filings (Ticker: VRXA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Veraxa Biotech - Post de-SPAC's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Veraxa Biotech - Post de-SPAC's regulatory disclosures and financial reporting.
Veraxa Biotech AG, a Swiss oncology-focused biotechnology company and emerging growth foreign private issuer, has filed a prospectus for the resale of up to 25,000,000 ordinary shares by Lincoln Park Capital Fund under a previously agreed purchase arrangement. These shares include 340,910 commitment shares already issued and up to 24,659,090 shares Veraxa may sell to Lincoln Park over a 24‑month term, tied to a total purchase commitment of up to $50,000,000. Veraxa will not receive proceeds from Lincoln Park’s resale of registered shares but may receive cash from future primary share sales to Lincoln Park under the Purchase Agreement, subject to a Beneficial Ownership Limitation of 4.99%, adjustable to 9.99%. Ordinary shares trade on Nasdaq Global Market under “VRXA” and warrants on Nasdaq Capital Market under “VRXAW.” Assuming all 25,000,000 shares are issued, ordinary shares outstanding would be 166,066,903. Veraxa emphasizes significant operating losses, need for substantial additional capital, clinical and regulatory risks for its oncology pipeline, and governance and disclosure differences arising from its Swiss domicile and foreign private issuer status.
VERAXA Biotech AG reported that it has strengthened its intellectual property around its BiTAC cancer therapy platforms. In the first half of 2026, the company filed initial patent applications for its T cell engager (BiTAC-TCE) and antibody-drug-conjugate (BiTAC-ADC) technologies and related therapeutic programs, while previously granted auxiliary technology patents have cleared their opposition period.
VERAXA now has more than 50 granted owned or exclusively licensed patents in 14 countries, spread across 26 patent families, and expects recently filed applications, once granted, to protect its core technology suite through at least 2047. The BiTAC approach uses dual-component constructs and click-chemistry-based "click-to-release" payload activation to enhance tumor selectivity, safety, and manufacturability of next-generation antibody-based therapies.
Veraxa Biotech AG reported that its bispecific antibody drug conjugate program VXA-222, developed under a joint discovery alliance with OmniAb, Inc., has achieved a key technical milestone and is moving into its next collaboration phase after OmniAb concluded its discovery work.
VXA-222 applies an “AND-gate” logic, targeting two different antigens on solid tumors with a single molecule. The collaboration, established in May 2025, combines OmniAb’s transgenic antibody discovery technologies with Veraxa’s proprietary ADC linker and conjugation platform. Veraxa will now establish the bsADC lead candidate, conduct in vitro and in vivo validation, and holds exclusive rights to develop and commercialize products using OmniAb-derived antibodies, while OmniAb is entitled to a share of specified revenue. Veraxa highlights this as part of its broader strategy to advance next-generation antibody-based cancer therapeutics.
Veraxa Biotech AG reports that shareholders at the 24 July 2026 Extraordinary General Meeting approved all Board proposals, with more than 99.94% of votes cast on 102,102,301 voting shares, representing 72.20% of share capital. The amendments are intended to support long-term growth and strategic flexibility.
The Articles state share capital of CHF 1,248,634 + 50/453, divided into 141,407,813 registered shares with a par value of CHF 100/11,325 each. New authorizations add conditional share capital for equity-linked instruments, merger-related options, and employee and advisory plans, plus a capital band permitting issuance of up to 70,662,564 additional shares until 31 December 2030, in defined cases with excluded or limited subscription rights.
Governance changes include increasing the maximum Board size from five to seven and detailed rules on compensation approval, stock-based incentives and outside mandates. Veraxa also highlighted progress on its BiTAC T-cell engager program and named Carl von Halem interim CFO and Christoph Erkel, Ph.D. as Chief Scientific Officer.
Veraxa Biotech AG reported new in vitro proof-of-concept data validating its novel BiTAC-ADC technology platform for more precise, tumor-restricted cancer treatment. In studies, BiTAC-ADCs discriminated between breast cancer and healthy cells and showed efficient, dose-dependent killing of 3D tumor cell spheroids.
The platform uses two complementary antibody-delivered precursors to keep payloads inactive in circulation and activate them only inside tumor cells, aiming to reduce off-tumor toxicity. Veraxa will attend the BIO International Convention in San Diego from June 22-25, 2026 to discuss partnering opportunities for its BiTAC-ADC and BiTAC-TCE platforms.